ScoreComparison
Why is RaQualia Pharma, Inc. ?
1
Poor Management Efficiency with a low ROE of 4.41%
- The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 62.14
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 62.14
- The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds
3
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.41%
4
The company has declared Positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at JPY 499.45 MM
- RAW MATERIAL COST(Y) Fallen by -10.8% (YoY)
- NET SALES(9M) Higher at JPY 3,124.52 MM
5
With ROE of 0.72%, it has a attractive valuation with a 1.43 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 2.97%, its profits have risen by 113% ; the PEG ratio of the company is 1.8
- At the current price, the company has a high dividend yield of 0
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to RaQualia Pharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is RaQualia Pharma, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
RaQualia Pharma, Inc.
2.97%
-0.04
78.45%
Japan Nikkei 225
43.58%
1.48
29.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.41%
EBIT Growth (5y)
41.24%
EBIT to Interest (avg)
75.61
Debt to EBITDA (avg)
22.67
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.33
Tax Ratio
78.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.90%
ROE (avg)
4.41%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
200
Industry P/E
Price to Book Value
1.43
EV to EBIT
42.13
EV to EBITDA
13.63
EV to Capital Employed
1.57
EV to Sales
2.54
PEG Ratio
1.79
Dividend Yield
0.00%
ROCE (Latest)
3.72%
ROE (Latest)
0.72%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at JPY 499.45 MM
RAW MATERIAL COST(Y)
Fallen by -10.8% (YoY
NET SALES(9M)
Higher at JPY 3,124.52 MM
NET PROFIT(9M)
Higher at JPY 391.59 MM
CASH AND EQV(HY)
Highest at JPY 9,190.92 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -25.67 %
DEBTORS TURNOVER RATIO(HY)
Highest at 4.98 times
-1What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 5.65 times
Here's what is working for RaQualia Pharma, Inc.
Net Sales
At JPY 3,124.52 MM has Grown at 37.4%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (JPY MM)
Net Profit
At JPY 391.59 MM has Grown at 179.93%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Operating Cash Flow
Highest at JPY 499.45 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (JPY MM)
Cash and Eqv
Highest at JPY 9,190.92 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -25.67 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 4.98 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at JPY 3,124.52 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (JPY MM)
Net Profit
Higher at JPY 391.59 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (JPY MM)
Raw Material Cost
Fallen by -10.8% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for RaQualia Pharma, Inc.
Inventory Turnover Ratio
Lowest at 5.65 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Footer loading
